Anti-Helicobacter pylori therapy in localized gastric mucosa-associated lymphoid tissue lymphoma

A prospective, nationwide, multicenter study in Japan

Katsuya Sugizaki, Akira Tari, Yasuhiko Kitadai, Ichiro Oda, Shotaro Nakamura, Tadashi Yoshino, Toshiro Sugiyama

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Helicobacter pylori eradication therapy was approved in Japan for the first-line, standard treatment of H. pylori-positive gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Although several retrospective studies or small-scale single-center studies have been reported, a prospective, large-scale, nationwide, multicenter study has not been reported from Japan. Materials and Methods: We conducted a prospective, nationwide, multicenter study to evaluate the clinical efficacy of rabeprazole-based triple H. pylori eradication therapy for patients with localized gastric MALT lymphoma in practice-based clinical trial. A total of 108 H. pylori-positive patients with stage I/II1 gastric MALT lymphoma underwent H. pylori eradication therapy. The primary endpoints were complete remission (CR) rate and the rate of transfer to secondary treatment. The secondary endpoints were CR maintenance duration and overall survival (OS). Results: CR of lymphoma was achieved in 84 of 97 patients (86.6%), during the period 2.0-44.7 months (median, 5.3 months) after starting H. pylori eradication treatment. CR was maintained in 77 of 81 patients (95.1%) for 0.4-53.2 months (median, 33.1 months). Secondary treatments (radiotherapy, rituximab, or gastrectomy) for gastric MALT lymphoma were needed in 10 of the 97 patients (10.31%). During follow-up, OS rate was 96.9% (94/97) and the causes of 3 deaths were not related to lymphoma. Conclusions: Rabeprazole-based H. pylori eradication therapy demonstrated a high CR rate, long CR maintenance, and a good OS for patients with localized gastric MALT lymphoma in this prospective, practice-based, multicenter study.

Original languageEnglish
Article numbere12474
JournalHelicobacter
Volume23
Issue number2
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Marginal Zone B-Cell Lymphoma
Gastric Mucosa
Helicobacter pylori
Multicenter Studies
Pylorus
Japan
Rabeprazole
Therapeutics
Lymphoma
Maintenance
Survival
Gastrectomy
Cause of Death
Radiotherapy
Survival Rate
Retrospective Studies
Clinical Trials

Keywords

  • gastric MALT lymphoma
  • Helicobacter pylori eradication
  • prospective nationwide multicenter study
  • rabeprazole-based triple therapy

ASJC Scopus subject areas

  • Gastroenterology
  • Infectious Diseases

Cite this

Anti-Helicobacter pylori therapy in localized gastric mucosa-associated lymphoid tissue lymphoma : A prospective, nationwide, multicenter study in Japan. / Sugizaki, Katsuya; Tari, Akira; Kitadai, Yasuhiko; Oda, Ichiro; Nakamura, Shotaro; Yoshino, Tadashi; Sugiyama, Toshiro.

In: Helicobacter, Vol. 23, No. 2, e12474, 01.04.2018.

Research output: Contribution to journalArticle

Sugizaki, Katsuya ; Tari, Akira ; Kitadai, Yasuhiko ; Oda, Ichiro ; Nakamura, Shotaro ; Yoshino, Tadashi ; Sugiyama, Toshiro. / Anti-Helicobacter pylori therapy in localized gastric mucosa-associated lymphoid tissue lymphoma : A prospective, nationwide, multicenter study in Japan. In: Helicobacter. 2018 ; Vol. 23, No. 2.
@article{5202ff77cdfc4686bc7cd365d60d6379,
title = "Anti-Helicobacter pylori therapy in localized gastric mucosa-associated lymphoid tissue lymphoma: A prospective, nationwide, multicenter study in Japan",
abstract = "Background: Helicobacter pylori eradication therapy was approved in Japan for the first-line, standard treatment of H. pylori-positive gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Although several retrospective studies or small-scale single-center studies have been reported, a prospective, large-scale, nationwide, multicenter study has not been reported from Japan. Materials and Methods: We conducted a prospective, nationwide, multicenter study to evaluate the clinical efficacy of rabeprazole-based triple H. pylori eradication therapy for patients with localized gastric MALT lymphoma in practice-based clinical trial. A total of 108 H. pylori-positive patients with stage I/II1 gastric MALT lymphoma underwent H. pylori eradication therapy. The primary endpoints were complete remission (CR) rate and the rate of transfer to secondary treatment. The secondary endpoints were CR maintenance duration and overall survival (OS). Results: CR of lymphoma was achieved in 84 of 97 patients (86.6{\%}), during the period 2.0-44.7 months (median, 5.3 months) after starting H. pylori eradication treatment. CR was maintained in 77 of 81 patients (95.1{\%}) for 0.4-53.2 months (median, 33.1 months). Secondary treatments (radiotherapy, rituximab, or gastrectomy) for gastric MALT lymphoma were needed in 10 of the 97 patients (10.31{\%}). During follow-up, OS rate was 96.9{\%} (94/97) and the causes of 3 deaths were not related to lymphoma. Conclusions: Rabeprazole-based H. pylori eradication therapy demonstrated a high CR rate, long CR maintenance, and a good OS for patients with localized gastric MALT lymphoma in this prospective, practice-based, multicenter study.",
keywords = "gastric MALT lymphoma, Helicobacter pylori eradication, prospective nationwide multicenter study, rabeprazole-based triple therapy",
author = "Katsuya Sugizaki and Akira Tari and Yasuhiko Kitadai and Ichiro Oda and Shotaro Nakamura and Tadashi Yoshino and Toshiro Sugiyama",
year = "2018",
month = "4",
day = "1",
doi = "10.1111/hel.12474",
language = "English",
volume = "23",
journal = "Helicobacter",
issn = "1083-4389",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Anti-Helicobacter pylori therapy in localized gastric mucosa-associated lymphoid tissue lymphoma

T2 - A prospective, nationwide, multicenter study in Japan

AU - Sugizaki, Katsuya

AU - Tari, Akira

AU - Kitadai, Yasuhiko

AU - Oda, Ichiro

AU - Nakamura, Shotaro

AU - Yoshino, Tadashi

AU - Sugiyama, Toshiro

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: Helicobacter pylori eradication therapy was approved in Japan for the first-line, standard treatment of H. pylori-positive gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Although several retrospective studies or small-scale single-center studies have been reported, a prospective, large-scale, nationwide, multicenter study has not been reported from Japan. Materials and Methods: We conducted a prospective, nationwide, multicenter study to evaluate the clinical efficacy of rabeprazole-based triple H. pylori eradication therapy for patients with localized gastric MALT lymphoma in practice-based clinical trial. A total of 108 H. pylori-positive patients with stage I/II1 gastric MALT lymphoma underwent H. pylori eradication therapy. The primary endpoints were complete remission (CR) rate and the rate of transfer to secondary treatment. The secondary endpoints were CR maintenance duration and overall survival (OS). Results: CR of lymphoma was achieved in 84 of 97 patients (86.6%), during the period 2.0-44.7 months (median, 5.3 months) after starting H. pylori eradication treatment. CR was maintained in 77 of 81 patients (95.1%) for 0.4-53.2 months (median, 33.1 months). Secondary treatments (radiotherapy, rituximab, or gastrectomy) for gastric MALT lymphoma were needed in 10 of the 97 patients (10.31%). During follow-up, OS rate was 96.9% (94/97) and the causes of 3 deaths were not related to lymphoma. Conclusions: Rabeprazole-based H. pylori eradication therapy demonstrated a high CR rate, long CR maintenance, and a good OS for patients with localized gastric MALT lymphoma in this prospective, practice-based, multicenter study.

AB - Background: Helicobacter pylori eradication therapy was approved in Japan for the first-line, standard treatment of H. pylori-positive gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Although several retrospective studies or small-scale single-center studies have been reported, a prospective, large-scale, nationwide, multicenter study has not been reported from Japan. Materials and Methods: We conducted a prospective, nationwide, multicenter study to evaluate the clinical efficacy of rabeprazole-based triple H. pylori eradication therapy for patients with localized gastric MALT lymphoma in practice-based clinical trial. A total of 108 H. pylori-positive patients with stage I/II1 gastric MALT lymphoma underwent H. pylori eradication therapy. The primary endpoints were complete remission (CR) rate and the rate of transfer to secondary treatment. The secondary endpoints were CR maintenance duration and overall survival (OS). Results: CR of lymphoma was achieved in 84 of 97 patients (86.6%), during the period 2.0-44.7 months (median, 5.3 months) after starting H. pylori eradication treatment. CR was maintained in 77 of 81 patients (95.1%) for 0.4-53.2 months (median, 33.1 months). Secondary treatments (radiotherapy, rituximab, or gastrectomy) for gastric MALT lymphoma were needed in 10 of the 97 patients (10.31%). During follow-up, OS rate was 96.9% (94/97) and the causes of 3 deaths were not related to lymphoma. Conclusions: Rabeprazole-based H. pylori eradication therapy demonstrated a high CR rate, long CR maintenance, and a good OS for patients with localized gastric MALT lymphoma in this prospective, practice-based, multicenter study.

KW - gastric MALT lymphoma

KW - Helicobacter pylori eradication

KW - prospective nationwide multicenter study

KW - rabeprazole-based triple therapy

UR - http://www.scopus.com/inward/record.url?scp=85043302145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043302145&partnerID=8YFLogxK

U2 - 10.1111/hel.12474

DO - 10.1111/hel.12474

M3 - Article

VL - 23

JO - Helicobacter

JF - Helicobacter

SN - 1083-4389

IS - 2

M1 - e12474

ER -